

Innovations in Breast Cancer Drug Development – Next Generation Oncology Trials Breast Cancer Workshop October 21, 2014

Co-sponsored by the U.S. Food and Drug Administration, American Association for Cancer Research,
American Society of Clinical Oncology, and the Breast Cancer Research Foundation

SPEAKERS

Laleh Amiri-Kordestani, MD

Medical Officer,
Division of Oncology Products 1,
Office of Hematology and Oncology
Products
Office of New Drugs, CDER, FDA

José Baselga, MD, PhD

Physician-in-Chief,
Memorial Sloan Kettering Cancer Center
New York, NY

Julia A. Beaver, MD

Medical Officer,
Division of Oncology Products 1,
Office of Hematology and Oncology
Products
Office of New Drugs, CDER, FDA

Patricia Cortázar, MD

Medical Team Leader,
Division of Oncology Products 1,
Office of Hematology and Oncology
Products
Office of New Drugs, CDER, FDA

Clifford A. Hudis, MD, FACP

Chief, Breast Cancer Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Lisa LaVange, PhD

Director,
Office of Biostatistics,
CDER, FDA

Elizabeth Mansfield, PhD

Director,
Personalized Medicine
Office of In Vitro Diagnostics and Radiological
Health,
CDRH, FDA

Larry Norton, MD

Medical Director,
Evelyn H. Lauder Breast Center
Memorial Sloan Kettering Cancer Center
New York, NY

Charles M. Perou, PhD

Professor of Genetics and Pathology
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill

Martine Piccart, MD, PhD

Head of Medicine Department
Institut Jules Bordet
Brussels, Belgium

David B. Solit, MD

Director,
Marie-Josée and Henry R. Kravis Center
For Molecular Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Victor Velculescu, MD, PhD

Professor of Oncology and
Co-Director Cancer Biology Program
Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Nikhil Wagle, MD

Dana-Farber Brigham and Women's
Cancer Center
Harvard University
Boston, MA

Innovations in Breast Cancer Drug Development – Next Generation Oncology Trials Breast Cancer Workshop October 21, 2014

Co-sponsored by the U.S. Food and Drug Administration, American Association for Cancer Research,
American Society of Clinical Oncology, and the Breast Cancer Research Foundation

PANELISTS

Gursel Aktan, MD, PhD

Associate Vice President
Breast PDT Leader
Merck Oncology
Upper Gwynedd, PA

Andrew R. Allen, BM, BCh, PhD

Executive Vice President
Clinical Development
Clovis Oncology
Boulder, CO

Fabrice André, MD, PhD

Professor, Department of Medical Oncology
Research Director, Head of INSERM Unit U981
Institut Gustave Roussy
Villejuif, France

Carlos L. Arteaga, MD

Professor of Medicine and Cancer Biology
Director, Breast Cancer Program
Vanderbilt-Ingram Cancer Center
Vanderbilt University,
Nashville, TN

Alan H. Auerbach, MD

Chief Executive Officer
President and Chairman of the Board
Puma Biotechnology,
Los Angeles CA

Philippe Bedard, MD, FRCPC

Staff Medical Oncologist
Princess Margaret Cancer Centre
Toronto, ON, Canada

Dietmar Berger, MD, PhD

Senior Vice President
Global Head of Clinical Development for
Hematology/Oncology Product Development
Genentech/Roche
San Francisco, CA

Monica M. Bertagnolli, MD

Alliance for Clinical Trials in Oncology
Dana-Farber Brigham and Women's Cancer
Center
Boston, MA

David Cameron, MD

Professor of Oncology
University of Edinburgh
Director of Cancer Services NHS Lothian
Edinburgh, Scotland

Lisa A. Carey, MD

Division Chief, Hematology and Oncology
Lineberger Comprehensive Cancer Center
The University of North Carolina,
Chapel Hill, NC

Nancy E. Davidson, MD

Hillman Professor of Oncology
Director, University of Pittsburgh Cancer Institute
and UPMC Cancer Center
Pittsburgh, PA

Angelo Di Leo, MD, PhD

Head, Dept. of Medical Oncology
Hospital of Prato, Istituto Toscano Tumori
Prato, Italy

Ute Dugan, MD, PhD

Executive Director, Oncology Global Clinical
Research R&D, Bristol-Myers-Squibb,
Wallingford, CT

Matthew Ellis, MB, BChir, PhD

Director, Lester and Sue Smith Breast Center
Baylor College of Medicine
Houston, TX

Elizabeth Frank, Ed.M

Patient Advocate
Dana Farber Cancer Institute
Boston, MA

Innovations in Breast Cancer Drug Development – Next Generation Oncology Trials Breast Cancer Workshop October 21, 2014

Co-sponsored by the U.S. Food and Drug Administration, American Association for Cancer Research,
American Society of Clinical Oncology, and the Breast Cancer Research Foundation

PANELISTS

Richard Gaynor, MD

Sr. Vice President,
Global Development and Medical Affairs
Oncology Eli Lilly and Company
Indianapolis IN

Richard D. Gelber, PhD

Professor in Biostatistics
Harvard School of Public Health
Harvard Medical School and
Dana-Farber Cancer Institute
Boston, MA

Karen A. Gelmon, MD, FRCPC

Professor Medicine,
University of British Columbia
Medical Oncologist, BC Cancer Agency,
Vancouver Cancer Centre
Head, Division of Medical Oncology, UBC
Vancouver, Canada

Charles E. Geyer, Jr. MD, FACP

Associate Director of Clinical Research
Virginia Commonwealth University Massey
Cancer Center
Richmond, VA

Luca Gianni, MD

Director Medical Oncology Department
San Raffaele Cancer Center
Milan, Italy

Nadia Harbeck, MD, PhD

Professor,
Women's Clinic Breast Cancer

Daniel F. Hayes, MD

Clinical Director, Breast Oncology Program
Stuart B. Padnos Professor of Breast Cancer
Research
University of Michigan Comprehensive Cancer
Center,
Ann Arbor, MI

Mia Levy, MD, PhD

Director Cancer Clinical Informatics
Ingram Cancer Center, Vanderbilt University
Nashville, TN

Sibylle Loibl, MD

Professor,
Co-chair, German Breast Cancer Group
GBH Forschungs GmbH,
Neu-Isenburg, Germany

Cristian Massacesi, MD

Vice-President, Senior Global Clinical Program
Head Oncology Global Development Paris Site
Novartis Pharmaceuticals
Paris, France

Musa Mayer, MS

Patient Advocate
AdvancedBC.org
New York, NY

Ben Ho Park, M.D., PhD

Associate Professor of Oncology,
Sidney Kimmel Comprehensive Cancer Center,
Johns Hopkins University
Baltimore, MD

Richard Pazdur, MD

Director,
Office of Hematology and Oncology Products,
Office of New Drugs,
CDER, FDA

Edith A. Perez, MD

Professor of Medicine and Deputy Director
Mayo Clinic Cancer Center
Jacksonville, FL

Markus Puhlmann, MD, MBA

Global Clinical Leader
Bayer Health Care
Whippany, NJ

Innovations in Breast Cancer Drug Development – Next Generation Oncology Trials Breast Cancer Workshop October 21, 2014

Co-sponsored by the U.S. Food and Drug Administration, American Association for Cancer Research,
American Society of Clinical Oncology, and the Breast Cancer Research Foundation

PANELISTS

Mary W. Redman, PhD

Associate Member
Fred Hutchison Cancer Research Center
Lead Biostatistician, SWOG Lung-MAP Study
Seattle, WA

David Reese, MD

Vice President, Translational Sciences
Amgen Inc.
Los Angeles, CA

Mace L. Rothenberg, MD

Senior Vice President
Clinical Development & Medical Affairs
Pfizer Oncology
New York, NY

Cristina Saura, MD

Breast Cancer Unit
Vall d'Hebron Hospital
Barcelona, Spain

Ellen V. Sigal, PhD

Chairperson
Friends of Cancer Research
Washington, DC

Lillian L. Siu, MD, FRCPC

Professor, University of Toronto
Princess Margaret Cancer Centre
Toronto, Canada

Dennis J. Slamon MD, PhD

Chief Division of Hematology and Oncology
University of California
Los Angeles, Ca

Joseph A. Sparano, MD

Associate Chairman,
Department of Medical Oncology and
Professor of Medicine and Women's Health,
Montefiore Einstein Center for Cancer Care
Bronx, NY

Patty Spears

Research Specialist and Patients' Advocate
North Carolina State University
Raleigh, NC

Vered Stearns, MD

Co-Director, Breast Cancer Program
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University,
Baltimore, MD

Sandra M. Swain, MD, FACP

Medical Director, Washington Cancer Institute
Professor of Medicine, Georgetown University
Washington, DC

Debasish Tripathy, MD

Professor and Chair,
Breast Medical Oncology
MD Anderson Cancer Center
Houston, TX

Eric P. Winer, MD

Chief, Division of Women's Cancers
Thompson Chair in Breast Cancer Research
Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School
Boston, MA

Antonio C. Wolff, MD

Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University,
Baltimore, MD

Norman Wolmark, MD

Chairman, National Surgical Adjuvant Breast &
Bowel Project (NSABP)
Professor of Surgery, Temple University School
of Medicine
Medical Director of Allegheny Health Network
Cancer Institute Research
Pittsburgh, Pa

Innovations in Breast Cancer Drug Development – Next Generation Oncology Trials Breast Cancer Workshop October 21, 2014

Co-sponsored by the U.S. Food and Drug Administration, American Association for Cancer Research,
American Society of Clinical Oncology, and the Breast Cancer Research Foundation

PANELISTS

Antoine Yver, MD, MSc

Senior Vice President & Head Oncology
Global Medicines Development
AstraZeneca,
Gaithersburg, MD

Jo Anne Zujewski, MD

Head, Breast Cancer Therapeutics
Cancer Therapy Evaluation Program
Division of Cancer Diagnosis and Treatment
National Cancer Institute,
Rockville, MD